Moderna Inc (MRNA) — Long-term Investment Intensity
Moderna Inc (MRNA) has a Long-term Investment Intensity of 19.6% as of March 2026. Long-term investments of $2.25 Billion represent 19.6% of total assets of $11.49 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See Moderna Inc shareholders equity for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Moderna Inc Long-term Investment Intensity (2016–2025)
This chart shows how Moderna Inc's Long-term Investment Intensity has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the intensity stands at 19.6%, reflecting long-term investments of $2.25 Billion against total assets of $11.49 Billion USD. Also explore MRNA total assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Moderna Inc (2016–2025)
The table below presents the year-by-year Long-term Investment Intensity for Moderna Inc from 2016 to 2025, covering 10 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see market cap of Moderna Inc.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 19.0% | $2.34 Billion | $12.34 Billion | ▲ +1.2 pp |
| 2024 | 17.7% | $2.51 Billion | $14.14 Billion | ▼ -8.0 pp |
| 2023 | 25.7% | $4.74 Billion | $18.43 Billion | ▼ -6.4 pp |
| 2022 | 32.2% | $8.32 Billion | $25.86 Billion | ▲ +4.4 pp |
| 2021 | 27.7% | $6.84 Billion | $24.67 Billion | ▲ +19.0 pp |
| 2020 | 8.7% | $638.85 Million | $7.34 Billion | ▼ -1.4 pp |
| 2019 | 10.1% | $159.99 Million | $1.59 Billion | ▲ +1.2 pp |
| 2018 | 8.8% | $172.99 Million | $1.96 Billion | ▼ -4.6 pp |
| 2017 | 13.4% | $145.85 Million | $1.08 Billion | ▼ -3.2 pp |
| 2016 | 16.7% | $236.57 Million | $1.42 Billion | — |